alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 530.21 Prohibitions for food-producing animals. ( a ) FDA may prohibit the extralabel use of an approved new animal or human drug or class of drugs in food-producing animals if FDA determines that: ( 1 ) An acceptable analytical method needs to be established and such method has not been established or cannot be established; or
( 2 ) The extralabel use of the drug or class of drugs presents a risk to the public health.
( b ) A prohibition may be a general ban on the extralabel use of the drug or class of drugs or may be limited to a specific species, indication, dosage form, route of administration, or combination of factors.
**Exhibit 31.2**

 

**CERTIFICATION OF PRINCIPALFINANCIAL OFFICER**

 

I, Douglas W. Cowan,certify that:

 

1. I have reviewed thisannual report on Form 10-K/A of Retractable Technologies, Inc.;

 

2. Based on my knowledge,this report does not contain any untrue statement of a material fact or omit tostate a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading withrespect to the period covered by this report;

 

3. Based on my knowledge,the financial statements, and other financial information included in thisreport, fairly present in all material respects the financial condition,results of operations, and cash flows of the registrant as of, and for, theperiods presented in this report;

 

4. The registrant’s othercertifying officer(s) and I are responsible for establishing and maintaining disclosurecontrols and procedures (as defined in Exchange Act Rules 13a-15(e) and15d-15(e)) for the registrant and have:

 

a)              Designed suchdisclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this report is being prepared;

 

b)             Evaluated theeffectiveness of the registrant’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of the disclosurecontrols and procedures, as of the end of the period covered by this reportbased on such evaluation; and

 

c)              Disclosed in thisreport any change in the registrant’s internal control over financial reportingthat occurred during the registrant’s most recent fiscal quarter (theregistrant’s fourth quarter in the case of an annual report) that hasmaterially affected, or is reasonably likely to materially affect, theregistrant’s internal control over financial reporting; and

 

5. Theregistrant’s other certifying officer(s) and I have disclosed, based on ourmost recent evaluation of internal control over financial reporting, to theregistrant’s auditors and the audit committee of the registrant’s board ofdirectors (or persons performing the equivalent functions):

 

a) All significantdeficiencies and material weaknesses in the design or operation of internalcontrol over financial reporting which are reasonably likely to adverselyaffect the registrant’s ability to record, process, summarize, and reportfinancial information; and

 

b) Any fraud, whether ornot material, that involves management or other employees who have asignificant role in the registrant’s internal control over financial reporting.

 
| Date February 26, 2008 |   |   |
|-----------------------------|--------|--------|
|                        |   |   |
| /s/ Douglas W.  Cowan       |   |   |
| DOUGLAS W. COWAN            |   |   |
| VICE PRESIDENT  AND         |   |   |
| CHIEF FINANCIAL  OFFICER    |   |   |
|                        |   |   |

 

----
<PAGE>   1
 
                                                                    EXHIBIT 23.3
 
                       CONSENT OF INDEPENDENT ACCOUNTANTS
 
     We hereby consent to the use in the Prospectus consisting part of this
Registration Statement on Form S-4 of Northland Cable Television, Inc. of our
reports dated October 10, 1997 relating to the financial statements of Aiken II
Cable Systems, a component of Robin Cable Systems, L.P., and the financial
statements of Greenwood Cable System a component of InterMedia Partners of
Carolina, L.P. which appear in such Prospectus. We also consent to the
references to us under the heading "Experts," "Summary Historical and Pro Forma
Consolidated Financial Data" and "Selected Historical and Pro Forma Consolidated
Financial Data" in such Prospectus. However, it should be noted that Price
Waterhouse LLP has not prepared or certified such "Summary Historical and Pro
Forma Consolidated Financial Data" or "Selected Historical and Pro Forma
Consolidated Financial Data."
 
PRICE WATERHOUSE LLP
 
San Francisco, California
December 23, 1997
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               DEC-31-1998
<CASH>                                           2,613
<SECURITIES>                                    24,743
<RECEIVABLES>                                   12,166
<ALLOWANCES>                                       957
<INVENTORY>                                      3,927
<CURRENT-ASSETS>                                48,465
<PP&E>                                          35,434
<DEPRECIATION>                                  16,959
<TOTAL-ASSETS>                                  72,291
<CURRENT-LIABILITIES>                           15,746
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            16
<OTHER-SE>                                      51,003
<TOTAL-LIABILITY-AND-EQUITY>                    72,291
<SALES>                                        107,601
<TOTAL-REVENUES>                               107,601
<CGS>                                           95,543
<TOTAL-COSTS>                                   95,543
<OTHER-EXPENSES>                                11,091
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 178
<INCOME-PRETAX>                                  2,297
<INCOME-TAX>                                       781
<INCOME-CONTINUING>                              1,516
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     1,516
<EPS-PRIMARY>                                      .24
<EPS-DILUTED>                                      .24
        

</TABLE>
<PAGE>   1
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the

                         Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 14, 1999

                              THE LOEWEN GROUP INC.

             (Exact name of registrant as specified in its charter)

<TABLE>
<S>                                            <C>                              <C>
        British Columbia, Canada                     0-18429                            98-0121376
    (State or other jurisdiction of            (Commission File Number)         (IRS Employer Identification No.)
            incorporation)
</TABLE>

<TABLE>
<S>                                                          <C>
         4126 Norland Avenue, Burnaby, British Columbia       V5G 3S8
             (Address of principal executive offices)        (zip code)
</TABLE>

Registrant's telephone number, including area code      604-299-9321

                                       N/A

          (Former name or former address, if changed since last report)

                                                      Exhibit Index is on page 3
                                                                     Page 1 of 4
<PAGE>   2
ITEM 5.           OTHER EVENTS.

Pursuant to Form 8-K, General Instructions F, registrant hereby incorporates by
reference the press release attached hereto as Exhibit 99.

ITEM 7.           FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND
                  EXHIBITS.

<TABLE>
<CAPTION>
                  Exhibit No.       Description
                  -----------       -----------
<S>                                 <C>
                  Exhibit 99        The Loewen Group Inc. Press Release dated
                                    April 14, 1999
</TABLE>

                                   SIGNATURES

                  Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

Dated: April 15, 1999

                                        THE LOEWEN GROUP INC.

                                        By:    /s/ Bradley D. Stam

                                        Name:  Bradley D. Stam

                                        Title: Senior Vice President, Law
<PAGE>   3
                                  EXHIBIT INDEX

<TABLE>
<CAPTION>
                                                                                        Sequential
Number            Exhibit                                                               Page Number
------            -------                                                               -----------
<S>               <C>                                                                   <C>
99                The Loewen Group Inc.                                                     4
                  Press Release dated April 14, 1999
</TABLE>
<PAGE>

                                                                    EXHIBIT 23.1


                   CONSENT OF INDEPENDENT ACCOUNTANTS

We hereby consent to the incorporation by reference in the Registration
Statements on Forms S-3 (No. 333-54132 and No. 333-46028) and Forms S-8 (No.
333-96081 and No. 333-66289) of IXYS Corporation of our report dated May 20,
2002, (except for Note 14 as to which the date is June 12, 2002), relating to
the financial statements which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP
San Jose, California
June 28, 2002
IN THE SUPREME COURT OF PENNSYLVANIA

MIDDLE DISTRICT

JPMORGAN CHASE BANK, NATIONAL

ASSOCIATION,

Respondent

v.

SEAN GALLAGHER AND HAIRONG

WANG,

Petitioners :

:

:

:

:

:

:

:

:

:

:

:

: No. 319 MAL 2019

Petition for Allowance of Appeal from the Order of the Superior Court

ORDER

PER CURIAM

AND NOW , this 16th day of October, 2019

, the Petition for Allowance of Appeal is

DENIED

.
800 Independence Ave.

Washington, DC 20591

February 4, 2014

Mr. Robert E. Cohn

Columbia Square

Hogan Lovells US LLP

555 Thirteenth Street, NW

. Washington, DC 20004

Dear Mr. Cohn :

This is in response to your March 21, 2013 letter (public docket No. FAA

- 2013

- 0294)

, cosigned by Mr. Patrick R. Rizzi, petiti oning the Federal Aviation Administration (FAA) on behalf of Republic Airline Inc. (“Republic”) for an exemption from § § 121.500

- 121.505 of

Title 14, Code of Federal Regulations (14 CFR)

. That exemption, if granted, would have

permitted Republic to operat e supplemental operations in accordance with the flight, duty,

and rest time requirements for domestic operations instead of those applicable to supplemental

operations.

On January 4, 2012 , the FAA issued the “Flightcrew Member Duty and Rest Requirements ”

final rule (77 FR 330) . This rule, effective January 4, 2014, created 14 CFR p art 117, which

replaces existing flight, duty, and rest time regulations for part 121 passenger operations.

Part 117 removes distinctions between domestic, supplemental , and flag passenger operations

in regard to flight, du ty, and rest time requirements.

Since the relief requested is covered under the new rule, we will take no further action on

your petition.

Sincerely,

/s/

Leslie H. Smith

Manager , Air Transportation D ivision2

Project No.: A FS

- 13

- 333

- E

Project Officer: _______________

ARM

- 10 1 : KJone s: 2/4/2014:Doc#37950

ARM

- 1/100/104:Program Office AFS

- 200

MR ROBERT E COHN

COLUMBIA SQUARE

HOGAN LOVELLS US LLP

555 THIRTEENTH STREET NW

WASHINGTON DC 20004
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from Balance
Sheet, Statement of operations, Statement of Cash Flows and Notes thereto 
incorporated in Part I, Item I of this Form 10-QSB and is qualified in its 
entirety by reference to such financial statements.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                       1,876,176
<SECURITIES>                                         0
<RECEIVABLES>                                  621,261
<ALLOWANCES>                                         0
<INVENTORY>                                     22,594
<CURRENT-ASSETS>                             2,654,289
<PP&E>                                          84,390
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                               4,748,948
<CURRENT-LIABILITIES>                        1,379,377
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                    400,000
<COMMON>                                        18,874
<OTHER-SE>                                   2,686,697
<TOTAL-LIABILITY-AND-EQUITY>                 4,748,948
<SALES>                                        275,487
<TOTAL-REVENUES>                                     0
<CGS>                                          169,843
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                               337,522
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              35,900
<INCOME-PRETAX>                              (267,778)
<INCOME-TAX>                                     1,350
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (269,078)
<EPS-PRIMARY>                                    (.03)
<EPS-DILUTED>                                        0
        

</TABLE>
**Exhibit 32.2**

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Wayside Technology Group, Inc (the “Company”) on Form 10-K for the period ending December 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kevin T. Scull, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)           The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)           The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 
| /s/   Kevin T. Scull                          |   |
|-----------------------------------------------|--------|
| Kevin   T. Scull                              |   |
| Vice   President and Chief Accounting Officer |   |
| February 18,   2011                      |   |

 

*A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by Company and furnished to the Securities and Exchange Commission or its staff upon request.*

 

----
§ 556.500 Oxytetracycline. ( a ) *Acceptable daily intake (ADI).* The ADI for total tetracycline residues (chlortetracycline, oxytetracycline, and tetracycline) is 25 μg/kg of body weight per day.
( b ) *Tolerances.* The tolerances for the sum of tetracycline residues are: ( 1 ) *Cattle.* ( i ) Muscle: 2 ppm.
( ii ) Liver: 6 ppm.
( iii ) Fat and kidney: 12 ppm.
( iv ) Milk: 0.3 ppm.
( 2 ) *Chickens and turkeys.* ( i ) Muscle: 2 ppm.
( ii ) Liver: 6 ppm.
( iii ) Fat and kidney: 12 ppm.
( 3 ) *Finfish.* Muscle (with adhering skin when edible): 2 ppm.
( 4 ) *Lobster.* Muscle: 2 ppm.
( 5 ) *Swine and sheep.* ( i ) Muscle: 2 ppm.
( ii ) Liver: 6 ppm.
( iii ) Fat and kidney: 12 ppm.
( 6 ) *Honey.* 750 ppb.
( c ) *Related conditions of use.* See §§ 520.1660c, 520.1660d, 520.1664, 522.1660a, 522.1660b, 522.1662, 522.1664, 529.1660, 558.450, and 558.455 of this chapter.
[84 FR 32993, July 11, 2019, as amended at 85 FR 18121, Apr. 1, 2020; 88 FR 16549, Mar. 20, 2023, 88 FR 55567, Aug. 16, 2023]
Michigan Supreme Court

Lansing, Michigan

Robert P. Young, Jr.

, Chief Justice

Stephen J. Markman

Mary Beth Kelly

Brian K. Zahra

Bridget M. McCormack

David F. Viviano

Richard H. Bernstein

, Justices 

# Order

September 16, 2015

150483

- 4

JAKE WILLIAMS, JR.,

Plaintiff,

v SC: 150483

COA: 312872

Wayne CC: 11

- 012265

- NF

ENJOI TRANSPORTATION SOLUTIONS,

LLC,

Defendant,

and

AMERICAN GUARANTEE AND

LIABILITY INSURANCE COMPANY,

Defendant

- Appellant,

and

FARM BUREAU MUTUAL INSURANCE

COMPANY OF MICHIGAN,

Defendant

- Appellee.

___________________________________/

FARM BUREAU MUTUAL INSURANCE

COMPANY OF MICHIGA N,

Plaintiff

- Appellee,

v SC: 150484

COA: 312882

Wayne CC: 10

- 010483

- NF

AMERICAN GUARANTEE AND

LIABILITY INSURANCE COMPANY,

Defendant

- Appellant,

and

ENJOI TRANSPORTATION SOLUTIONS,

LLC,

Defendant.

____________________________________/I, Larry S. Royster, Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

September 16, 2015

a0909 2

Clerk On order of the Court, the application for leave to appeal t he October 9, 2014

judgment of the Court of Appeals is considered, and it is DENIED, because we are not

persuaded that the question presented should be reviewed by this Court.
#### § 573.960 Sorbitan monostearate.

The food additive sorbitan monostearate may be safely used alone or in combination with polysorbate 60 as an emulsifier in mineral premixes and dietary supplements for animal feeds.
UNITED STATES ENVIRONMENTAL PROTECTION AGENCY REGION IX AIR DIVISION

Technical Support Document

for EPA ’ s Rulemaking for the Arizona State Implementation Plan

Article 2. Ambient Air Quality Standards; Area Designations; Classifications, Section R 18

- 2

- 2 10

. Attainment, Nonattainment, and Unclassifiable Area Designations

Prepared by: Vanessa Graham Reviewed by: Andrew Steckel

March 20161

RULE IDENTIFICATION

- Agency Arizona Department of Environmental Quality

SIP Approved Rule Arizona Administrative Code ( AAC ) Article 2, Section R 18

- 2

-

210 . Attainment, Nonattainment, and Unclassifiable Area Designations. Submitted

– October 29, 2012

. Approved

– 79 FR 56656

, September 23, 2014

.
Subject of this TSD AAC R18

- 2

- 210 . Attainment, Nonattainment, and

Unclassifiable Area Designations. Amended

– July 1, 2014

. Submitted

– December 21, 2015

.
Completeness Finding Determination of completeness letter: March 21, 2016.

RULE SUMMARY

– AAC s ection R 18

- 2

- 210 updates Arizona’s incorporation by reference status for national ambient air quality standard ( NAAQS ) pollutants as defined in the July 2014 update to 40 CFR 81.303. 40 CFR 81.303 addresses the nonattainment
status and containment boundaries for NAAQS pollutants in Arizona.

EPA EVALUATION CRITERIA

- Generally, SIP rules must be enforceable (see section 1 10(a) of the Clean Air Act ( CAA ) ) and must not relax existing requirements

. CAA §110(l) prohibits EPA from approving any SIP revision that would interfere with any applicable requirement concerning attainment and reasonable further progress (RFP)
or any other applicable requirement of the CAA. In addition, CAA §193 prohibits the modification of any SIP

- approved control requirement in effect before November 15, 1990, in a nonattainment area.

EPA ACTION

- AAC R 18

- 2

- 210 is clear and adequately compl ies with CAA sections 110(a), 110(l), 193, and other provisions of the Act . Approval of these revision replaces previously

- approved but now outdated provisions in the Arizona SIP. EPA staff recommends approval of R 18

- 2

- 210.

REFERENCES

-

1. 79 FR 56656

, September 23, 2014

.
§ 211.115 Reprocessing. ( a ) Written procedures shall be established and followed prescribing a system for reprocessing batches that do not conform to standards or specifications and the steps to be taken to insure that the reprocessed batches will conform with all established standards, specifications, and characteristics.
( b ) Reprocessing shall not be performed without the review and approval of the quality control unit.
§ 573.500 Condensed, extracted glutamic acid fermentation product. Condensed, extracted glutamic acid fermentation product may be safely used in animal feed under the following conditions: ( a ) The additive is a concentrated mixture of the liquor remaining from the extraction of glutamic acid, combined with the cells of *Corynebacterium glutamicum* used to produce the glutamic acid.
( b ) It is used or intended for use as follows: ( 1 ) In poultry feed as a source of protein in an amount not to exceed 5 percent of the total ration.
( 2 ) In cattle feed as a source of protein in an amount not to exceed 10 percent of the feed.
( c ) In order to assure safe use, the label and labeling of the additive shall bear, in addition to the other information required by the Act, the following: ( 1 ) The name of the additive.
( 2 ) A statement of the concentration of the additive contained in any mixture.
( 3 ) Adequate directions for use.
[41 FR 38652, Sept. 10, 1976, as amended at 89 FR 33231, Apr. 29, 2024]
#### § 343.20 [Reserved]
§ 522.850 Estradiol valerate and norgestomet in combination. ( a ) *Specifications.* The product is a two-component drug consisting of the following: ( 1 ) An implant containing 6.0 milligrams of norgestomet.
( 2 ) An injectable solution (sesame oil) containing 3.0 milligrams of norgestomet and 5.0 milligrams of estradiol valerate per 2 milliliters.
( b ) *Sponsor.* See 000010 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.240 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Amount.* One implant and 2 milliliters of injection at time of implantation.
( 2 ) *Indications for use.* For synchronization of estrus/ovulation in cycling beef cattle and non-lactating dairy heifers.
( 3 ) *Limitations.* Insert implant subcutaneously in the ear only; then immediately inject solution intramuscularly only. Counting the day of implantation as day 1, remove the implant on day 10. Collect all implants as they are removed and burn them. While animals are restrained for artificial insemination, avoid other treatments such as vaccinations, dipping, pour-on grub and louse prevention, spraying, etc. When inseminating without estrus detection, the entire treated group should be started at 48 hours after the last implant has been removed and should be completed within 6 hours. Where estrus detection is preferred, insemination should be approximately 12 hours after first detection of estrus. Those that do not conceive can be re-bred when they return to estrus approximately 17 to 25 days after implant removal. Do not use in cows producing milk for human consumption.
[47 FR 55477, Dec. 10, 1982, as amended at 48 FR 49656, Oct. 27, 1983; 51 FR 33592, Sept. 22, 1986; 54 FR 1165, Jan. 12, 1989; 84 FR 39184, Aug. 9, 2019; 84 FR 32992, July 11, 2019]